Needham & Company LLC Reaffirms Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD)‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a research note issued to investors on Thursday, MarketBeat.com reports. They presently have a $41.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 102.77% from the stock’s current price.

Several other research analysts have also weighed in on ACAD. Royal Bank Of Canada upped their target price on shares of ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. HC Wainwright restated a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 6th. Bank of America restated a “buy” rating and set a $14.50 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Stifel Nicolaus upped their target price on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 21st. Finally, Citigroup upped their target price on shares of ACADIA Pharmaceuticals from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.76.

ACADIA Pharmaceuticals Trading Down 1.5%

Shares of ACADIA Pharmaceuticals stock traded down $0.31 on Thursday, reaching $20.22. 2,512,917 shares of the stock were exchanged, compared to its average volume of 1,712,075. ACADIA Pharmaceuticals has a 1-year low of $19.69 and a 1-year high of $30.96. The business has a fifty day moving average price of $27.41 and a two-hundred day moving average price of $24.18. The firm has a market capitalization of $3.48 billion, a PE ratio of 9.11 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. The business had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. During the same period in the previous year, the business posted $0.16 earnings per share. The business’s revenue was up 16.4% compared to the same quarter last year. Research analysts expect that ACADIA Pharmaceuticals will post 0.64 EPS for the current year.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Mark Schneyer sold 14,292 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $29.22, for a total value of $417,612.24. Following the sale, the executive vice president owned 67,828 shares of the company’s stock, valued at $1,981,934.16. This represents a 17.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth Thompson sold 16,558 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $26.13, for a total transaction of $432,660.54. Following the completion of the sale, the executive vice president directly owned 18,994 shares in the company, valued at $496,313.22. This trade represents a 46.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 36,699 shares of company stock worth $1,019,894 in the last ninety days. Insiders own 26.20% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ACAD. Rice Hall James & Associates LLC purchased a new position in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $15,658,000. State of Wyoming purchased a new position in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $1,234,000. Bank of America Corp DE lifted its stake in shares of ACADIA Pharmaceuticals by 27.2% during the first quarter. Bank of America Corp DE now owns 1,553,770 shares of the biopharmaceutical company’s stock valued at $34,587,000 after buying an additional 332,325 shares during the period. Virtus Advisers LLC purchased a new position in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $1,123,000. Finally, GSA Capital Partners LLP purchased a new position in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $1,783,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering weight-banded dosing of trofinetide, the active ingredient in Daybue for Rett syndrome. The patent is expected to extend U.S. protection through March 2041, supporting a longer commercial runway and potentially limiting generic competition. Acadia Announces Trofinetide Patent Allowance
• Positive Sentiment: Analyst coverage continues to reflect confidence in Acadia’s longer-term growth: HC Wainwright maintained a Buy rating and a $33 price target, while projecting rising EPS from $1.87 in fiscal 2027 to $3.40 in fiscal 2030. HC Wainwright ACAD Earnings Estimate
• Neutral Sentiment: HC Wainwright made small downward revisions to its fiscal 2027–2030 EPS estimates, trimming forecasts by $0.02 per share in each year. The reductions are modest, but suggest slightly lower expectations for future profitability despite the continued Buy rating.
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of ACADIA investors. The announcement does not establish wrongdoing, but shareholder investigations can add reputational and legal uncertainty and pressure sentiment. Pomerantz ACAD Investor Alert
• Negative Sentiment: Unusually heavy put-option activity indicated increased bearish positioning: traders purchased 6,078 puts, about 323% above average daily volume, with puts substantially outnumbering calls. ACAD Put Options Activity

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for neurological and psychiatric disorders. The company is headquartered in San Diego, California, and conducts research and commercial activities primarily in the United States.

ACADIA’s marketed products include NUPLAZID (pimavanserin), an atypical antipsychotic approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also markets DAYBUE (trofinetide), a therapy for Rett syndrome, a rare neurodevelopmental disorder.

Founded in 1993, ACADIA continues to advance a pipeline of therapies for central nervous system conditions, including additional neurological and psychiatric disorders.